These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 1824678)

  • 21. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
    Cavé H; van der Werff ten Bosch J; Suciu S; Guidal C; Waterkeyn C; Otten J; Bakkus M; Thielemans K; Grandchamp B; Vilmer E
    N Engl J Med; 1998 Aug; 339(9):591-8. PubMed ID: 9718378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct sequence analysis of TCR V delta 2-D delta 3 rearrangements in common acute lymphoblastic leukaemia and application to detection of minimal residual disease.
    Langlands K; Eden OB; Micallef-Eynaud P; Parker AC; Anthony RS
    Br J Haematol; 1993 Aug; 84(4):648-55. PubMed ID: 8217823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of clonal immunoglobulin heavy chain and I cell receptor gamma gene rearrangements during progression of childhood acute lymphoblastic leukemia.
    Marshall GM; Kwan E; Haber M; Brisco MJ; Sykes PJ; Morley AA; Toogood I; Waters K; Tauro G; Ekert H
    Leukemia; 1995 Nov; 9(11):1847-50. PubMed ID: 7475273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Residual disease detection in multiple follow-up samples in children with acute lymphoblastic leukemia.
    Kitchingman GR
    Leukemia; 1994 Mar; 8(3):395-401. PubMed ID: 8127144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow-up of minimal residual disease in childhood acute lymphoblastic leukemia patients by polymerase chain reaction analysis of multiple clone-specific or malignancy-specific gene markers.
    Kuang S; Gu L; Dong S; Cao Q; Xu C; Huang W; Su XY; Huang QH; Xie JX; Chen SJ; Chen Z
    Cancer Genet Cytogenet; 1996 Jun; 88(2):110-7. PubMed ID: 8640718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia.
    Pongers-Willemse MJ; Seriu T; Stolz F; d'Aniello E; Gameiro P; Pisa P; Gonzalez M; Bartram CR; Panzer-Grümayer ER; Biondi A; San Miguel JF; van Dongen JJ
    Leukemia; 1999 Jan; 13(1):110-8. PubMed ID: 10049045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A polymerase chain reaction study of the stability of Ig heavy-chain and T-cell receptor delta gene rearrangements between presentation and relapse of childhood B-lineage acute lymphoblastic leukemia.
    Steward CG; Goulden NJ; Katz F; Baines D; Martin PG; Langlands K; Potter MN; Chessells JM; Oakhill A
    Blood; 1994 Mar; 83(5):1355-62. PubMed ID: 8118037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring.
    Germano G; del Giudice L; Palatron S; Giarin E; Cazzaniga G; Biondi A; Basso G
    Leukemia; 2003 Aug; 17(8):1573-82. PubMed ID: 12886245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unusual T-cell receptor-delta gene rearrangement patterns revealed by screening of a large series of childhood acute lymphoblastic leukaemia by multiplex polymerase chain reaction.
    Seeger K; Taube T; Eckert C; Hanel C; Pogodda M; Henze G
    Br J Haematol; 2001 May; 113(2):318-22. PubMed ID: 11380394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of detection of monoclonality in remission marrow in acute lymphoblastic leukemia in childhood. Australian and New Zealand Children's Cancer Study Group.
    Brisco MJ; Condon J; Hughes E; Neoh SH; Nicholson I; Sykes PJ; Tauro G; Ekert H; Waters K; Toogood I
    Leukemia; 1993 Oct; 7(10):1514-20. PubMed ID: 8412313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro amplification of T cell gamma gene rearrangements: a new tool for the assessment of minimal residual disease in acute lymphoblastic leukemias.
    d'Auriol L; Macintyre E; Galibert F; Sigaux F
    Leukemia; 1989 Feb; 3(2):155-8. PubMed ID: 2536129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IgH/TCR delta PCR oligonucleotide liquid hybridization, a fast and sensitive assay for monitoring minimal residual disease in childhood B-precursor ALL.
    Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; von dem Borne AE; van der Schoot CE
    Leukemia; 1995 Jan; 9(1):216-22. PubMed ID: 7845021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heterogeneity of the T-cell receptor delta gene indicating subclone formation in acute precursor B-cell leukemias.
    Ghali DW; Panzer S; Fischer S; Argyriou-Tirita A; Haas OA; Kovar H; Gadner H; Panzer-Grümayer ER
    Blood; 1995 May; 85(10):2795-801. PubMed ID: 7742540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogeneic IgH probes and the polymerase chain reaction.
    Nizet Y; Van Daele S; Lewalle P; Vaerman JL; Philippe M; Vermylen C; Cornu G; Ferrant A; Michaux JL; Martiat P
    Blood; 1993 Sep; 82(5):1618-25. PubMed ID: 8364210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes.
    Pongers-Willemse MJ; Verhagen OJ; Tibbe GJ; Wijkhuijs AJ; de Haas V; Roovers E; van der Schoot CE; van Dongen JJ
    Leukemia; 1998 Dec; 12(12):2006-14. PubMed ID: 9844931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterisation of non-concordance in the T-cell receptor gamma chain genes at presentation and clinical relapse in acute lymphoblastic leukemia.
    Taylor JJ; Rowe D; Kylefjord H; Chessells J; Katz F; Proctor SJ; Middleton PG
    Leukemia; 1994 Jan; 8(1):60-6. PubMed ID: 8289500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Minimal residual disease detection using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: Slovak experience.
    Kolenova A; Hikkel I; Ilencikova D; Hikkelova M; Sejnova D; Kaiserova E; Cizmar A; Puskacova J; Bubanska E; Oravkinova I; Gencik M
    Neoplasma; 2010; 57(6):552-61. PubMed ID: 20845994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human common acute lymphoblastic leukemia-derived cell lines are competent to recombine their T-cell receptor delta/alpha regions along a hierarchically ordered pathway.
    Hansen-Hagge TE; Yokota S; Reuter HJ; Schwarz K; Bartram CR
    Blood; 1992 Nov; 80(9):2353-62. PubMed ID: 1421406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minimal residual disease quantification in childhood acute lymphoblastic leukemia by real-time polymerase chain reaction using the SYBR green dye.
    Li AH; Forestier E; Rosenquist R; Roos G
    Exp Hematol; 2002 Oct; 30(10):1170-7. PubMed ID: 12384148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Minimal residual disease (MRD) monitoring using rearrangement of T-cell receptor and immunoglobulin H gene in the treatment of adult acute lymphoblastic leukemia patients.
    Toubai T; Tanaka J; Ota S; Fukuhara T; Hashino S; Kondo T; Kasai M; Kakinoki Y; Masauzi N; Morioka M; Kawamura T; Iwasaki H; Asaka M; Imamura M
    Am J Hematol; 2005 Nov; 80(3):181-7. PubMed ID: 16247752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.